UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6

Benzinga Newsdesk www.benzinga.com Negative 84.1%

Neg 84.1% Neu 0% Pos 0%

UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.

Comments

No comments yet. Be the first!